Stock Ratings / Health Care / ASBP / financials

CALC (47) BIVI (33) BOLT (28) GTBP (46) ⌘ Pro Terminal →

Aspire-Lakewood Holdings Inc. (ASBP) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$8.48 -4.50% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.40

Aspire-Lakewood Holdings Inc. (ASBP) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $11.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $8.40 (-1.00%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-11.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ASBP)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (33/100 Composite)

🔍 WHY ASBP SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$8.30+5.8% Next Q

Q2 (-2Q)

Grade E$8.78+0.2% Next Q

Q3 (-1Q)

Grade E$8.80-3.6% Next Q

Current

Grade E$8.48-8.9% Hist 90D α

Trajectory: E (25) → E (33)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ASBP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ASBP currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.55) and Max Pain ($8.90) forces dealer call-delta covering toward $16.38.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ASBP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ASBP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 33%NO 67%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How ASBP Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $1.0M

FY24

Rev $1.0M

FY25

Rev $6.2K

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$6.2K	-1.9%	-80%	-$24.5M	-$4.9M	-45%
FY 2024	$1.0M	8%	-121.1%	-$1.3M	-$265.2K	-45%
FY 2023	$1.0M	8%	0%	$4.5M	-$653.1K	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ASBP)

✓Walkthrough of ASBP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ASBP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +3754.55%🛡️ HOLDING TREND SUPPORT

2026-10-30O $8.46H $8.48L $8.00C $8.48VOL 20.3K

RES: $11.12SUP: $7.69SMA50: $8.55SMA200: $4.82

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ASBP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ASBP Butterfly Map → + Track ASBP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ASBP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ASBP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ASBP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ASBP)

Health Care Rank #882 of 1016 ⚔️ CALC vs ASBP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ASBP vs. CALC, BIVI, BOLT, GTBP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Aspire-Lakewood Holdings Inc. (ASBP) ranks #882 by composite RQD confidence (33/100, grade E) and #881 by equity capitalization ($11.9M). Within this direct 5-issuer industry benchmark cohort, ASBP leads on earnings valuation at N/A trailing P/E, while ASBP leads on capital efficiency and profitability with -35.0% ROIC and -1.9% gross margin. CALC currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with ASBP at 33/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ASBP ACTIVE Aspire-Lakewood Holdings Inc.	E	33/100	—	-1.9%	-35.0%	-4.50%	$11.9M	Benchmark Subject
CALC CalciMedica Inc.	D	47/100	—	—	-35.0%	+5.42%	$11.9M	/calc-vs-asbp →
BIVI BioVie Inc. (Class A)	E	33/100	—	—	-35.0%	-5.48%	$12.0M	/bivi-vs-asbp →
BOLT Bolt Biotherapeutics Inc.	E	28/100	—	—	-35.0%	-3.34%	$12.3M	/bolt-vs-asbp →
GTBP GT Biopharma Inc.	D	46/100	—	—	-35.0%	+1.63%	$11.5M	/gtbp-vs-asbp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001847345

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aspire-Lakewood Holdings Inc. (ASBP) reported GAAP revenue of $6.2K (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$24.5M, operating cash flow of -$4.9M, and free cash flow of -$4.9M (-1756.6% YoY). On the balance sheet, ASBP closed FY2025 with $1.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$6.2K	-$24.5M	-$4.9M	-$4.9M	$1.3M	—
FY2024 (FY)	2024-12-31	$0	-$1.3M	-$265.2K	-$265.2K	$148.0K	—
FY2023 (FY)	2023-12-31	$0	$4.5M	-$653.1K	-$653.1K	—	—

3. ASBP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ASBP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Aspire-Lakewood Holdings Inc. (NASDAQ: ASBP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $8.48 (-4.50% 1D, market cap $11.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ASBP ranks #882 in composite RQD confidence.

How does ASBP compare to CALC and BIVI in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ASBP carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of -1.9%, and ROIC of -35.0%. By comparison, CALC (CalciMedica Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $11.9M) and BIVI (BioVie Inc. (Class A)) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $12.0M). Among the 5-stock peer group, ASBP leads on earnings multiple (N/A) while ASBP leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ASBP?

Per ASBP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001847345), Aspire-Lakewood Holdings Inc. generated $6.2K in revenue, -$24.5M in net income, and -$4.9M in free cash flow against $1.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ASBP trading relative to its 50-day, 200-day, and 52-week technical levels?

ASBP last traded at $8.48 (-4.50% on volume of 31,114 shares), positioning the stock -0.82% below its 50-day simple moving average ($8.55) and +75.93% above its 200-day simple moving average ($4.82). Across its 52-week range of $0.11 to $15.60, ASBP sits at the 54.0% percentile with a 14-day RSI of 45.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.42 to $9.54).

ASBP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Aspire-Lakewood Holdings Inc. (ASBP)?

In FY 2025 (10-K), ASBP converted $1.0M of revenue into a 0% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: ASBP RQD Cockpit ASBP 12M Forecast ASBP Earnings & Move ASBP Dividends & DRIP ASBP Insiders & 13F ASBP Whale Options ASBP Profit Sankey ASBP News & Why